Global Vulvodynia Treatment Market Set to Exceed USD 8 Billion by 2028, Driven by Advancements in Pain Management and Therapeutic Approaches

The global market for vulvodynia treatment is poised for significant growth, with revenue expected to surpass USD 8 billion by 2028, according to a recent report by Future Market Insights. Currently valued at USD 5.6 billion, the market is projected to achieve a remarkable Compound Annual Growth Rate (CAGR) of 6.3% between 2022 and 2028.

Vulvodynia treatment holds a substantial share of 73.4% in the global neuropathic pain market, with North America and Western Europe leading in demand. However, recent analysis indicates a slight negative growth in Basis Point Share (BPS) in the first half of 2022 compared to projections, attributed partly to decreased adoption of topical treatments due to side effects and reduced patient follow-up.

Get Access to Sample Now:

Despite this, the market is witnessing significant advancements in pain neuroscience, particularly in understanding central sensitization for managing vulvodynia. These developments are contributing to positive BPS growth in the first half of 2022 over the previous year.

Key developments in the market include the integration of physical therapy, conversation therapy, and sexological treatment alongside traditional approaches. Additionally, biofeedback therapy, local anesthetics, nerve block injections, pelvic floor therapy, and surgical interventions have emerged as effective management strategies for vulvodynia and related chronic female disorders.

“We are at an exciting juncture in the vulvodynia treatment market, with innovative approaches reshaping patient care and outcomes,” said a Future Market Insights. “As research continues to advance and new therapies emerge, we anticipate substantial growth opportunities and improved quality of life for patients worldwide.”

Key Takeaways: Vulvodynia Treatment Market Growth

  • The global vulvodynia treatment market is expected to reach over USD 8 billion by 2028, with a strong growth rate (CAGR) of 6.3%.
  • North America holds the largest market share (30.2%) due to a high prevalence of vulvodynia (6 million women affected).
  • Western and Eastern Europe are projected to capture a combined 30.6% share due to rising treatment popularity and research.
  • Latin America and Asia Pacific (APEJ) show promise with 10.1% and 19.6% shares respectively, driven by factors like generic drug availability in APEJ.
  • The Middle East & Africa region has a smaller share (3.2%) but is expected to accelerate by the end of the forecast period.

Get Customization on This Report:

Competitive Landscape:

To address the growing number of patients with vulvodynia, companies are investing more in research and development, as well as in mergers and acquisitions, to find effective therapies and medications. This strategy enables them to expand their target market, reaching both global and domestic audiences.

Key Companies Profiled:

  • Eli Lilly and Company
  • AstraZeneca Plc.
  • GlaxoSmithKline Plc.
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Allergan plc

Key Segments of Vulvodynia Treatment Industry Survey:

Vulvodynia Treatment Market by Drug Class:

  • Local Anesthetics
  • Anticonvulsant
  • Tricyclic Antidepressants
  • Hormones
  • Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
  • Nerve Blocks
  • Others

 Vulvodynia Treatment Market by Mode of Application:

  • Oral Vulvodynia Treatment
  • Topical Vulvodynia Treatment
  • Injection Vulvodynia Treatment

 Vulvodynia Treatment Market by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Online Pharmacies

 Vulvodynia Treatment Market by Region:

  • North America Vulvodynia Treatment Market
  • Latin America Vulvodynia Treatment Market
  • Europe Vulvodynia Treatment Market
  • East Asia Vulvodynia Treatment Market
  • South Asia & Pacific Vulvodynia Treatment Market
  • Middle East & Africa (MEA) Vulvodynia Treatment Market

Get Complete Full Report:

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries:
LinkedInTwitterBlogs | YouTube

Leave a comment

Your email address will not be published. Required fields are marked *